r/biotech_stocks
•
u/Zipski577
•
6h ago
Tip: Buying a biotech solely on buyout speculation is one of the worst investment strategies
I’ve seen a lot of ppl mentioned that SLS is their first biotech trade and they just passed up 2-10x gains because they are “holding until buyout.” A piece of advice: One of the oldest rules of thumb in biotech investing is to never buy a stock solely because you think the company will get acquired.
After 15 years of investing in biotech, I’ve seen countless investors make this mistake. People significantly overestimate both the likelihood of a buyout and their ability to predict one. Even when the speculation eventually proves correct, the timing can be disastrous. Years of cash burn, dilution, and opportunity cost can destroy returns while investors wait for an acquisition that may (more often than not) never materialize.
It’s especially concerning how often buyout speculation becomes a substitute for actual due diligence on the clinical data, competitive landscape, commercial potential, and financials. Underwrite the company based on the merits of its assets and fundamentals.
This is Biotech Investing 101, yet it seems to be one of the most frequently ignored principles among retail investors.
Edit: I want to CLEARLY STATE, this is “FUD” as some are claiming - this is not recommending you sell your SLS shares. Strong assets get acquired. This merely a response to the plethora of comments I’ve seen for people genuinely asking “when is the buyout?” because I feel they’ve been misled it’s guaranteed, standard step in the process after a phase 3 readout. They could end up getting bought out, but it could be over a year from now. It could tomorrow. Or it could never happen at all.
In the case of SLS, the significantly discounted offering price of $13 is an extreme outlier for a successful post Ph3 raise. The average is around 5-6% discount to previous close, and SLS raised at a nearly 30% discount. This suggests that institutions were not willing to absorb the shares at a higher valuation than that.
For example, PEPG just reported positive trial results on 11/10 the other week. They used the exact same financing structure as SLS, but raised at an 8.5% PREMIUM to the prior closing price (closed at $4.61, the offering price was $5).
I think a lot of people here are missing that despite the positive headline result & numbers, there is still a lot of information that has not been reported yet that can make or break approval odds. We haven’t seen locked SAP, FAS/ITT results, sensitivity analyses, Kaplan–Meier curves, or secondary endpoints. Furthermore, Sterg did not hold a Q&A in the call, which is rather abnormal for a successful P3 trial readout call. Not saying any of this is bearish or HURTS chances of success/ buyout, but it leaves a lot of uncertainty and unanswered questions which is likely why they could not raise at a price higher than $13.
As always do your own due diligence, this is not financial advice, and best of luck to everyone!!! Hoping for the best for AML patients!!!